Go Pro
NASDAQ:STTK

Shattuck Labs Q2 2026 Earnings Report

Shattuck Labs logo
$6.10 -0.21 (-3.26%)
As of 03:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Shattuck Labs EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.12
Beat/Miss
Beat by +$0.00
One Year Ago EPS
N/A

Shattuck Labs Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Shattuck Labs Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Tuesday, August 11, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Shattuck Labs' Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Shattuck Labs Earnings Headlines

Contrasting Shattuck Labs (NASDAQ:STTK) and AnaptysBio (NASDAQ:ANAB)
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Shattuck Labs: A Receptor-Side Bet On The TL1A Boom
See More Shattuck Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shattuck Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shattuck Labs and other key companies, straight to your email.

About Shattuck Labs

Shattuck Labs (NASDAQ:STTK) is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to create bifunctional fusion proteins that combine immune-cell activation with the targeted blocking of immune-suppressive pathways.

Shattuck’s lead investigational programs are intended to stimulate antitumor immune responses within the tumor microenvironment. Its pipeline has included ARC therapeutics designed to combine CD40 agonism with checkpoint inhibition, including SL-172154, which has been evaluated in clinical studies involving patients with advanced solid tumors. These products remain investigational and have not been approved for commercial use.

Founded in 2016 and headquartered in Austin, Texas, Shattuck Labs has advanced its programs through early-stage clinical development and collaborations with research and medical institutions. The company is led by President and Chief Executive Officer Taylor Schreiber, M.D., Ph.D. Shattuck’s shares trade on the Nasdaq under the symbol STTK.

View Shattuck Labs Profile